<p>Monte Rosa Therapeutics, Inc.（纳斯达克代码：GLUE - 获取免费报告）周一股价上涨 10.8%，此前富国银行将其目标股价从 10.00 美元上调至 13.00 美元。富国银行目前对该股票维持平等权重评级。Monte Rosa Therapeutics 的股价最高曾达到 13.59 美元，最后交易价为 13.64 美元。在交易过程中，约有 448,769 股易手，较 836,201 股的日均成交量下降了 46%。该股票此前收于 12.31 美元。</p>
<p>另外，Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Monte Rosa Therapeutics 股票的 “卖出（d+）” 评级。两位投资分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，Monte Rosa Therapeutics 目前的平均评级为 “持有”，平均目标股价为 16.33 美元。</p>
<p><strong>查看我们关于 GLUE 的最新研究报告</strong></p>
<h2>对 Monte Rosa Therapeutics 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近调整了对 GLUE 的持仓。Pallas Capital Advisors LLC 在第二季度购买了 Monte Rosa Therapeutics 的新股份，价值约 59,000 美元。American Century Companies Inc.在第一季度将其在 Monte Rosa Therapeutics 的持股增加了 30.7%。American Century Companies Inc.目前拥有 100,406 股该公司的股票，价值 466,000 美元，此前在此期间又收购了 23,556 股。CWM LLC 在第二季度将其在 Monte Rosa Therapeutics 的股份增加了 664.3%。CWM LLC 目前拥有 28,326 股该公司的股票，价值 128,000 美元，此前在此期间又购买了 24,620 股。Nuveen LLC 在第一季度购买了 Monte Rosa Therapeutics 的新股份，价值约 546,000 美元。最后，Brighton Jones LLC 在第二季度获得了 Monte Rosa Therapeutics 的新股份，价值 48,000 美元。79.96% 的股票由机构投资者持有。</p>
<h2>Monte Rosa Therapeutics 股票表现</h2>
<p>该股票市值为 8.9052 亿美元，市盈率为 42.67，贝塔值为 1.61。该股票的 50 日移动平均线为 8.43 美元，200 日移动平均线为 6.03 美元。</p>
<p>Monte Rosa Therapeutics（纳斯达克代码：GLUE - 获取免费报告）最后一次公布财报是在 11 月 6 日星期四。该公司报告本季度每股收益（EPS）为-0.33 美元，超出分析师一致预期的-0.39 美元，超出幅度为 0.06 美元。该季度的营业收入为 1277 万美元，而分析师预期为 737 万美元。Monte Rosa Therapeutics 的净利润率为 11.54%，股本回报率为 8.20%。分析师预测 Monte Rosa Therapeutics, Inc.本年度将发布-1.49 的每股收益。</p>
<h2>Monte Rosa Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Monte Rosa Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发新型小分子精准药物，利用人体自然机制选择性降解具有治疗相关性的蛋白质。该公司开发了 MRT-2359，这是一种口服生物可用的分子胶降解剂，针对翻译终止因子蛋白 GSPT1，用于治疗 MYC 驱动的肿瘤；MRT-6160 用于治疗系统性和中枢神经系统自身免疫疾病；以及 MRT-8102 用于治疗 IL-1?/NLRP3 驱动的炎症性疾病。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Monte Rosa Therapeutics</li>
<li>每月分红股票的利与弊</li>
<li>盈利胜利与股票下跌：D-Wave 发生了什么？</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>在市场回调时显示相对强势的三只股票</li>
<li>什么是分红之王？</li>
<li>如果市场持续下滑，值得关注的五只防御性消费股</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Monte Rosa Therapeutics 吗？</h2>
<p>在您考虑投资 Monte Rosa Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Monte Rosa Therapeutics 并不在名单上。</p>
<p>虽然 Monte Rosa Therapeutics 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GLUE

<p>蒙特罗莎治疗公司（NASDAQ:GLUE）股价上涨 10.8%，因富国银行将其目标价从 10.00 美元上调至 13.00 美元，并维持 “持平” 评级。该股最高交易价达到 13.59 美元，最后交易价为 13.64 美元。尽管如此，Weiss Ratings 重申了 “卖出（d+）” 评级。机构投资者持有该股 79.96% 的股份。公司报告每股收益为（0.33 美元），超出预期，季度收入为 1277 万美元。分析师预测当前年度每股收益为-1.49 美元</p>

<p>Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Get Free Report) shares rose 10.8% on Monday after Wells Fargo &amp; Company raised their price target on the stock from $10.00 to $13.00. Wells Fargo &amp; Company currently has an equal weight rating on the stock. Monte Rosa Therapeutics traded as high as $13.59 and last traded at $13.64. Approximately 448,769 shares changed hands during trading, a decline of 46% from the average daily volume of 836,201 shares. The stock had previously closed at $12.31.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics, Inc.（纳斯达克代码：GLUE - 获取免费报告）周一股价上涨 10.8%，此前富国银行将其目标股价从 10.00 美元上调至 13.00 美元。富国银行目前对该股票维持平等权重评级。Monte Rosa Therapeutics 的股价最高曾达到 13.59 美元，最后交易价为 13.64 美元。在交易过程中，约有 448,769 股易手，较 836,201 股的日均成交量下降了 46%。该股票此前收于 12.31 美元。</p>
</div><p>Separately, Weiss Ratings reaffirmed a &#34;sell (d+)&#34; rating on shares of Monte Rosa Therapeutics in a research report on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Monte Rosa Therapeutics presently has an average rating of &#34;Hold&#34; and an average price target of $16.33.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 31 日星期五的研究报告中重申了对 Monte Rosa Therapeutics 股票的 “卖出（d+）” 评级。两位投资分析师给予该股票买入评级，一位给予持有评级，一位给予卖出评级。根据 MarketBeat 的数据，Monte Rosa Therapeutics 目前的平均评级为 “持有”，平均目标股价为 16.33 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on GLUE</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 GLUE 的最新研究报告</strong></p>
</div><h2>Hedge Funds Weigh In On Monte Rosa Therapeutics</h2>
<div class="lb-trans"><h2>对 Monte Rosa Therapeutics 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of GLUE. Pallas Capital Advisors LLC purchased a new position in shares of Monte Rosa Therapeutics during the second quarter worth approximately $59,000. American Century Companies Inc. grew its holdings in Monte Rosa Therapeutics by 30.7% during the first quarter. American Century Companies Inc. now owns 100,406 shares of the company's stock worth $466,000 after acquiring an additional 23,556 shares during the period. CWM LLC grew its stake in shares of Monte Rosa Therapeutics by 664.3% during the 2nd quarter. CWM LLC now owns 28,326 shares of the company's stock worth $128,000 after purchasing an additional 24,620 shares during the period. Nuveen LLC purchased a new position in Monte Rosa Therapeutics during the first quarter worth approximately $546,000. Finally, Brighton Jones LLC acquired a new position in Monte Rosa Therapeutics during the second quarter worth $48,000. 79.96% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近调整了对 GLUE 的持仓。Pallas Capital Advisors LLC 在第二季度购买了 Monte Rosa Therapeutics 的新股份，价值约 59,000 美元。American Century Companies Inc.在第一季度将其在 Monte Rosa Therapeutics 的持股增加了 30.7%。American Century Companies Inc.目前拥有 100,406 股该公司的股票，价值 466,000 美元，此前在此期间又收购了 23,556 股。CWM LLC 在第二季度将其在 Monte Rosa Therapeutics 的股份增加了 664.3%。CWM LLC 目前拥有 28,326 股该公司的股票，价值 128,000 美元，此前在此期间又购买了 24,620 股。Nuveen LLC 在第一季度购买了 Monte Rosa Therapeutics 的新股份，价值约 546,000 美元。最后，Brighton Jones LLC 在第二季度获得了 Monte Rosa Therapeutics 的新股份，价值 48,000 美元。79.96% 的股票由机构投资者持有。</p>
</div><h2>Monte Rosa Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Monte Rosa Therapeutics 股票表现</h2>
</div><p>The stock has a market cap of $890.52 million, a PE ratio of 42.67 and a beta of 1.61. The stock's 50-day moving average is $8.43 and its two-hundred day moving average is $6.03.</p>
<div class="lb-trans"><p>该股票市值为 8.9052 亿美元，市盈率为 42.67，贝塔值为 1.61。该股票的 50 日移动平均线为 8.43 美元，200 日移动平均线为 6.03 美元。</p>
</div><p>Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.06. The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.20%. Analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 EPS for the current year.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics（纳斯达克代码：GLUE - 获取免费报告）最后一次公布财报是在 11 月 6 日星期四。该公司报告本季度每股收益（EPS）为-0.33 美元，超出分析师一致预期的-0.39 美元，超出幅度为 0.06 美元。该季度的营业收入为 1277 万美元，而分析师预期为 737 万美元。Monte Rosa Therapeutics 的净利润率为 11.54%，股本回报率为 8.20%。分析师预测 Monte Rosa Therapeutics, Inc.本年度将发布-1.49 的每股收益。</p>
</div><h2>Monte Rosa Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Monte Rosa Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.</p>
<div class="lb-trans"><p>Monte Rosa Therapeutics, Inc.是一家临床阶段的生物技术公司，专注于开发新型小分子精准药物，利用人体自然机制选择性降解具有治疗相关性的蛋白质。该公司开发了 MRT-2359，这是一种口服生物可用的分子胶降解剂，针对翻译终止因子蛋白 GSPT1，用于治疗 MYC 驱动的肿瘤；MRT-6160 用于治疗系统性和中枢神经系统自身免疫疾病；以及 MRT-8102 用于治疗 IL-1?/NLRP3 驱动的炎症性疾病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Monte Rosa Therapeutics</li>
<li>Pros And Cons Of Monthly Dividend Stocks</li>
<li>An Earnings Win With a Stock Slump: What's Happening With D-Wave?</li>
<li>Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?</li>
<li>3 Stocks Showing Relative Strength as Markets Pull Back</li>
<li>What is a Dividend King?</li>
<li>5 Defensive Consumer Plays to Watch If Markets Keep Slipping</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Monte Rosa Therapeutics</li>
<li>每月分红股票的利与弊</li>
<li>盈利胜利与股票下跌：D-Wave 发生了什么？</li>
<li>房地产投资信托是否值得在您的投资组合中占有一席之地？</li>
<li>在市场回调时显示相对强势的三只股票</li>
<li>什么是分红之王？</li>
<li>如果市场持续下滑，值得关注的五只防御性消费股</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Monte Rosa Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Monte Rosa Therapeutics 吗？</h2>
</div><p>Before you consider Monte Rosa Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑投资 Monte Rosa Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Monte Rosa Therapeutics 并不在名单上。</p>
</div><p>While Monte Rosa Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Monte Rosa Therapeutics 目前在分析师中获得持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Monte Rosa Therapeutics（纳斯达克股票代码：GLUE）在分析师上调评级后股价上涨 10.8%